In this study, we administered apatinib in combination with anti-epidermal growth factor receptor (EGFR) targeted and systemic chemotherapy for the treatment of oral cancer and to achieve better disease outcomes. The gene discussed is EGFR; the disease is lip and oral cavity carcinoma.